STOCK TITAN

NLS Pharmaceutics Ltd - NLSP STOCK NEWS

Welcome to our dedicated news page for NLS Pharmaceutics (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on NLS Pharmaceutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NLS Pharmaceutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NLS Pharmaceutics's position in the market.

Rhea-AI Summary
NLS Pharmaceutics has received a notice from Nasdaq stating that it is not in compliance with the minimum bid price requirement. The company has 180 days to regain compliance by maintaining a minimum bid price of $1.00 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
none
-
Rhea-AI Summary
NLS Pharmaceutics has received a notice from Nasdaq stating that it is not in compliance with the minimum bid price requirement. The company has 180 days to regain compliance by maintaining a minimum bid price of $1.00 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
NLS Pharmaceutics postpones company update due to important developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
none
Rhea-AI Summary
NLS Pharmaceutics postpones company update due to important developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.55%
Tags
none
-
Rhea-AI Summary
NLS Pharmaceutics to issue important update on strategic discussions and Phase 3 timeline
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.64%
Tags
partnership
-
Rhea-AI Summary
NLS Pharmaceutics to issue important update on strategic discussions and Phase 3 timeline
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
Rhea-AI Summary
NLS Pharmaceutics CEO issues letter to shareholders, highlights progress and future plans
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.64%
Tags
none
-
Rhea-AI Summary
NLS Pharmaceutics CEO issues letter to shareholders, highlights progress and future plans
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25%
Tags
none
-
Rhea-AI Summary
NLS Pharmaceutics announces FDA approval for Phase 3 study of Mazindol ER in narcolepsy patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
clinical trial
Rhea-AI Summary
NLS Pharmaceutics announces FDA approval for Phase 3 study of Mazindol ER in narcolepsy patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.17%
Tags
clinical trial
NLS Pharmaceutics Ltd

Nasdaq:NLSP

NLSP Rankings

NLSP Stock Data

7.12M
18.78M
31.54%
14.99%
0.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Switzerland
Zurich

About NLSP

mission & values to serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. we value partnership and integrity, we are ethical and responsible and show respect and compassion for our patients. r&d strategy the successful companies of tomorrow are those that go beyond delivering products to delivering real solutions and services. r&d is the cornerstone of our company and we promote ingenuity through an effective intellectual property policy. the advancements in science mean that more targeted, more (cost-)effective treatments are within reach and we are here to take on this challenge. our innovative r&d is centered on patients’ needs and delivering affordable, safe and effective solutions. not only will these enable us to improve access to quality healthcare and meet unmet needs, but they will also deliver the sustainable growth required to allow us to continue to invest in innovative research & developm